Drug Trial Radar · NCT07038369
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
134
Planned (sponsor's estimate)
Start
Jul 29, 2025
Primary completion
Aug 31, 2028
Study completion Jan 31, 2029
Sponsor
- Lead sponsor
- Atavistik Bio, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/HER2- advanced and metastatic breast cancer, with or without fulvestrant.
Conditions
- Advanced Solid Tumors
- Breast Cancer
- Breast Carcinoma
- Breast Neoplasms
- ER Positive Breast Cancer
- Cervical Cancers
- Cervical Neoplasms
- Cervical Carcinoma
- Triple Negative Breast Cancer
- Gynecologic Cancers
- Gynecologic Neoplasm
- Endometrial Cancer
- Endometrial Neoplasm
- Endometrial Carcinoma (EC)
- Fallopian Cancer
- Ovarian Carcinoma
- Ovarian Cancer
- Ovarian Neoplasms
- Prostate Cancers
- Prostate Carcinoma
- Solid Tumors
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Uterine Neoplasms
- Genital Neoplasms, Female
- Urogenital Neoplasms
Interventions
ATV-1601Drug
Drug: ATV-1601 • Oral ATV-1601
ATV-1601 + FulvestrantCombination product
Drug: ATV-1601 * Oral ATV-1601 Drug: Fulvestrant * Intramuscular Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Expansion: Maximum and minimum plasma concentrationTime frame: Approximately 48 months.
- Expansion: Time to C MaxTime frame: Approximately 48 months
- Expansion: Area under the concentration-time curveTime frame: Approximately 48 months
- Expansion: AUC at end of dosing intervalTime frame: Approximately 48 months
- Expansion: AUC extrapolated to infinityTime frame: Approximately 48 months
- Expansion: Half-lifeTime frame: Approximately 48 months
- Expansion: Trough ConcentrationsTime frame: Approximately 48 months
- Escalation & Expansion: Safety and Tolerability of monotherapy.Time frame: Approximately 48 months.
- Escalation: Maximum tolerated dose and/or recommended phase 2 dose of ATV-1601 in monotherapy.Time frame: Approximately 48 months.
- Escalation: Maximum tolerated dose and/or recommended phase 2 dose of ATV-1601 combination with fulvestrant.Time frame: Approximately 48 months.
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California
Florida Cancer Specialists & Research Institute - Lake Mary
Lake Mary, Florida
Massachusetts General Hospital
Boston, Massachusetts
Washington University
St Louis, Missouri
MD Anderson Cancer Center
Houston, Texas
Centre Leon Berard
Lyon, France
National Cancer Centre Singapore
Singapore, Singapore
START Madrid - CIOCC
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.